PUBLICATIONS

1. Jun-Lun Meng#, Zi-Xuan Dong#, Yan-Ru Chen#, Meng-Hsuan Lin, Yu-Ching Liu, Steve R. Roffler, Wen-Wei Lin, Chin-Yuan Chang, Shey-Cherng Tzou, TianLu Cheng, Hsiao-Chen Huang, Zhi-Qin Li, Yen-Cheng Lin, and Yu-Cheng Su* (2025). pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma. ACS Nano. doi.org/10.1021/acsnano.4c05906. (IF = 15.8)
2. Chiao-Yu Hsiao, Jun-Lun Meng, Jung-Zhe Hong, Xuan-Huong Ly, Meng-Hsuan Lin, Chin-Yuan Chang, Minh-Tram T. Nguyen, Tian-Lu Cheng, Wen-Wei Lin, Pierre-Alain Burnouf, Talal Salem Al-Qaisi, En-Shuo Liu, and Yu-Cheng Su*. (2022). Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules. Bioconjugate Chemistry. doi.org/10.1021/acs.bioconjchem.2c00416. (IF = 6.069)
3. Pierre-Alain Burnouf* , Steve R. Roffler, Chia-Ching Wu, Yu-Cheng Su. (2022). Glucuronides: From biological waste to bio-nanomedical applications. Journal of Controlled Release. 349: 765-782. (IF = 11.467)
   
4. Minh-Tram T. Nguyen, Yu-Chien Shih, Meng-Hsuan Lin, Steve R. Roffler, Chiao-Yu Hsiao, Tian-Lu Cheng, Wen-Wei Lin, En-Chi Lin, Yuh-Jyh Jong, Chin-Yuan Chang* & Yu-Cheng Su*. (2022). Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Communications Chemistry. 5: 88. (IF = 7.211)
5. Kai-Wen Ho, I.-J.u Chen, Yi-An Cheng, Tzu-Yi Liao, En-Shuo Liu, Huei-Jen Chen, Yun-Chi Lu, Yu-Cheng Su, Steve R. Roffler, Bo-Cheng Huang, Hui-Ju Liu, Ming-Yii Huang, Chiao-Yun Chen & Tian-Lu Cheng* . (2021). Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. Journal of Nanobiotechnology. 19: 16. (IF=9.429) 
   
6. Even Chen, Bing-Mae Chen, Yu-Cheng Su, Yuan-Chih Chang, Tian-Lu Cheng, Yechezekel Barenholz*, and Steve R. Roffler*. (2020). Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex. ACS Nano. 14: 7808-7822 . (IF= 18.027)
   
7. Chen IJ, Cheng YA, Ho KW, Lin WW, Cheng KW, Lu YC, Hsieh YC, Huang CC, Chuang CH, Chen FM, Su YC, Roffler SR, Cheng TL*. (2020). Bispecific Antibody (HER2 × mPEG) Enhances Anti-Cancer Effects by Precise Targeting and Accumulation of mPEGylated Liposomes. Acta Biomaterialia. S1742-7061(20)30226-9. (IF= 10.633 )
8. Lee CC*† , Su YC† , Ko TP† , Lin LL, Yang CY, Chang SC, Roffler SR* , Wang HJ*. (2020). Structural basis of polyethylene glycol recognition by antibody. Journal of Biomedical Science. 27(1):12. († contributed equally to this work. IF= 12.771)
9. Cheng YA, Chen IJ, Su YC, Cheng KW, Lu YC, Lin WW, Hsieh YC, Kao CH, Chen FM, Roffler SR* , Cheng TL*. (2019). Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer. Biomaterials Science. 7: 3404-3417. (IF=7.59)
10. Chen YJ, Chen M, Hsieh YC, Su YC, Wang CH, Cheng CM, Kao AP, Wang KH, Cheng JJ, Chuang KH*. Development of a highly sensitive enzyme-linked immunosorbent assay (ELISA) through use of poly-protein G-expressing cell-based microplates. Scientific Reports. 8: 17868. (IF = 4.122, Rank = 12/64, 18.75%) 
    
11. Al-Qaisi TS, Su YC, Roffler SR*. (2018). Transient AID expression for in situ mutagenesis with improved cellular fitness. Scientific Reports. 8: 9413. (IF = 4.122, Rank = 12/64, 18.75%)
    
12. Burnouf PA, Leu YL, Su YC, Wu K, Wei-Chi Lin, Roffler SR*. (2018). Reversible glycosidic switch for secure delivery of molecular nanocargos. Nature Communications. 9:1843 (IF = 12.353, Rank =3/64, 4.68%)
13. Chen BM, Al-Aghbar MA, Lee CH, Chang TC, Su YC, Li YC, Chang SE, Chen CC, Chung TH, Liao YC, Lee CH, Roffler SR. (2017). The Affinity of Elongated Membrane-Tethered Ligands Determines Potency of T Cell Receptor Triggering. Frontiers in Immunology. 8:793. (IF = 5.511, Rank =30/155, 19.35%)
14. Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, Lee MT, Chen YT, Roffler SR* and Wu JY*. (2017). A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nature Communications. 8:522. (IF = 12.353, Rank =3/64, 4.68%)
15. Su YC, Burnouf PA, Chuang KH, Chen BM, Cheng TL, Roffler SR. (2017). Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nature Communications. 8:15507. (IF = 12.353, Rank =3/64, 4.68%)
16. Hao WR, Chen M, Chen YJ, Su YC, Cheng CM, Hsueh HY , Kao AP, Hsieh YC, Chang Johny, Tseng MY, Chuang KH. (2017). Poly-protein G-expressing bacteria enhance the sensitivity of immunoassays. Scientific Reports. 7: 989. (IF = 4.122, Rank = 12/64, 18.75%)
17. Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, Cheng TL, Chen YT, Wu JY, Roffler SR. (2016). Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. Analytical Chemistry. 88:10661-66. (IF = 6.042, Rank = 4/80, 5%)
18. Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK, Cheng TL, and Roffler SR. (2016). Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. ACS Nano. 10:648-62 (IF = 13.709, Rank = 10/171, 5.84%)
19. Tung HY, Su YC, Chen BM, Burnouf PA, Huang WC, Chuang KH, Yan YT, Cheng TL, Roffler SR. (2015). Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies. Molecular Cancer Therapeutics. 14:1317-26. (IF = 5.365, Rank = 42/222, 18.9%)
20. Su YC, Al-Qaisi TS, Tung HY, Cheng TL, Chuang KH, Chen BM, Roffler SR. (2014). Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies. mAbs. 6:1069-83. (IF = 5.165, Rank = 18/133, 13.53%)
21. Su YC, Cheng TC, Leu YL, Roffler SR, Wang JY, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL. (2014). PET imaging of β-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy. Molecular Cancer Therapeutics. 13: 2852-2863. (IF = 5.365, Rank = 42/222, 18.9%)
22. Cheng TC, Chuang KH, Chen M, Wang HE, Tzou SC, Su YC, Chuang CH, Kao CH, Chen BM, Chang LS, Roffler SR, Cheng TL. (2013) Sensitivity of PEGylated interferon detection by anti-polyethylene glycol (PEG) antibodies depends on PEG length. Bioconjugate chemistry. 24: 1408-13. (IF = 4.485, Rank = 10/79, 12.65%)
23. Cheng TC, Roffler SR, Tzou SC, Chuang KH, Su YC, Chuang CH, Kao CH, Chen CS, Harn IH, Liu KY, Cheng TL, Leu YL. (2012). An activity-based near-infrared glucuronide trapping probe for imaging β-glucuronidase expression in deep tissues. Journal of the American Chemical Society. 134:3103-3110. (IF = 14.357, Rank = 8/171, 4.67%)
24. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR. (2010). Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjugate chemistry. 21:1264-1270. (IF = 4.485, Rank = 10/79, 12.65%)
25. Tzou SC, Roffler SR, Chuang KH, Yeh HP, Kao CH, Su YC, Cheng CM, Tseng WL, Shiea J, Harm IH, Cheng KW, Chen BM, Hwang JJ, Cheng TL, Wang HE. (2009). Micro-PET imaging of beta-glucuronidase activity by the hydrophobic conversion of a glucuronide probe. Radiology. 16:83-90. (IF = 7.296, Rank = 2/126, 1.58%)
26. Cheng CM, Chu PY, Chuang KH, Roffler SR, Kao CH, Tseng WL, Shiea J, Chang WD, Su YC, Chen BM, Wang YM, Cheng TL. (2009). Hapten-derivatized nanoparticle targeting and imaging of gene expression by multimodality imaging systems. Cancer Gene Therapy. 16:83-90. (IF = 4.044, Rank = 27/160, 16.87%)
27. Cheng CM, Lu YL, Chuang KH, Hung WC, Shiea J, Su YC, Kao CH, Chen BM, Roffler SR, Cheng TL. (2008). Tumor-targeting prodrug-activating bacteria for cancer therapy. Cancer Gene Therapy. 15:393-401. (IF = 3.652, Rank = 38/158, 24%)
28. Su YC, Chuang KH, Wang YM, Cheng CM, Lin SR, Wang JY, Hwang JJ, Chen BM, Chen KC, Roffler SR, Cheng TL. (2007). Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored β-glucuronidase. Gene Therapy. 14:565-574. (IF = 3.203, Rank = 48/160, 30%)
29. Chuang KH, Cheng CM, Roffler SR, Lu YL, Lin SR, Wang JY, Tzou WS, Su YC, Chen BM, Cheng TL. (2006). Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Bioconjugate chemistry. 17:707-714. (IF = 4.485, Rank = 10/79, 12.65%)